Tyme Technologies : Inc - Corporate Presentation

T Y M E I N C . C O M / N A S D A Q : T Y M E

N o v e m b e r 2 0 2 1

I n v e s t o r P r e s e n t a t i o n

S c i e n t i f i c S o l u t i o n s W i t h o u t C o m p r o m i s e

T Y M E I N C . C O M

Safe Harbor Statement

In addition to historical information, this presentation contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this presentation include, without limitation, statements regarding our drug candidates (including SM-88 and TYME- 18) and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical or clinical trials, including the proposed TYME-19proof-of-concept study, preliminary data results and the therapeutic design and mechanisms of our drug candidates. The words "believes," "expects," "hopes," "may," "will," "plan," "intends," "estimates," "could," "should," "would," "continue," "seeks," "anticipates," and similar expressions (including their use in the negative) are intended to identify forward-looking statements. Forward-looking statements can also be identified by discussions of future matters such as: the effect of the novel coronavirus (COVID-19) pandemic and the associated impact on the national and global economy as well as impacts on the Company's ongoing clinical trials and ability to analyze data from those trials; the cost of development and potential commercialization of our lead drug candidate and of other new products; expected releases of interim or final data from our clinical trials; possible collaborations; and the timing, scope, status, objectives of our ongoing and planned trials; the success of management transitions; and other statements that are not historical. The forward-looking statements contained in this presentation are based on management's current expectations and projections which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any historical results and future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include but are not limited to: the severity, duration, and economic impact of the COVID-19 pandemic; that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply, and in the ability to achieve adequate start and completion dates, as well as uncertainties in clinical trial design and patient enrollment, dropout or discontinuation rates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trials may differ from prior or preliminary study data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 or other drug candidates may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88 or other drug candidates; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned "Risk Factors" of TYME's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on June 10, 2021 as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission available at www.sec.gov.

2

T Y M E I N C . C O M

TYME's Investment Rationale

TYME has a platform therapy that has demonstrated broad activity across 15 cancer types as seen in first-in-human

study and in a compassionate use program

Robust pipeline with SM-88 in multiple indications

• PRECISION PROMISE Trial - Phase 2/3 trial in pancreatic cancer
• OASIS Trial - Phase 2 metastatic HR+/HER2- breast cancer with Georgetown University
• HopES Trial - Phase 2 advanced sarcomas

Biomarkers initiative around SM-88 to develop targeted approach

• Partnering with Evotec, a global drug development company, and pre-eminent medical institutions: Georgetown University, NYU Medical Center, and the Mayo Clinic

Seeking to develop novel tumor targeting technology with newly issued patent

Strong IP portfolio with more than 200 patent applications granted or pending globally

New management team with broad biopharmaceutical industry experience

Well-funded to advance programs: $96.6MM`in cash as of 9/30/21

3

Exploiting Cancer's Unique Metabolism through Modified Amino Acids

1. TYME's modified dysfunctional tyrosine selectively consumed by cancer cells

-88 SM

-88 SM

SM-88

5. Reduce immunosuppressive cells in tumor

2. Protein synthesis fails	3. Decreased
cellular defenses

4. Cell death from oxidative stress

Free radical

(ROS) production

4

T Y M E I N C . C O M

		Pipeline
	F O U N D A T I O N A L M O A & B I O M A R K E R S T R A T E G Y T O S U P P O R T P I P E L I N E
P R O G R A M	I N D I C A T I O N	P R E C L I N I C A L	P H A S E 1	P H A S E 2	P H A S E 3
O N C O L O G Y
	Pancreatic			PRECISION
	(Second-Line)			PROMISE
SM-88	Breast Cancer			OASIS
Oral	(HR+/HER2-)
	Metastatic Sarcomas			HopES
SM-88i	Multiple Oncology Indications
Injectable	(Alternative Formulation)
TYME-18	Solid Tumors
Intra-tumoral
TYME-T3
Tumor Targeting	Solid Tumors
Technology
V I R A L

TYME-19	COVID-19
Oral

5